CCR5-Δ32 polymorphism: a possible protective factor for post-stroke depressive symptoms.
Journal
Journal of psychiatry & neuroscience : JPN
ISSN: 1488-2434
Titre abrégé: J Psychiatry Neurosci
Pays: Canada
ID NLM: 9107859
Informations de publication
Date de publication:
22 07 2021
22 07 2021
Historique:
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
19
1
2022
Statut:
epublish
Résumé
A naturally occurring loss-of-function mutation in the gene for C-C chemokine receptor type 5 (CCR5-Δ32) has recently been reported as a protective factor in post-stroke motor and cognitive recovery. We sought to examine whether this mutation also prevented the development of depressive symptoms up to 2 years after a stroke. Participants were survivors of a first-ever mild to moderate ischemic stroke or transient ischemic attack from the TABASCO prospective study who underwent a 3 T MRI at baseline and were examined by a multiprofessional team 6, 12 and 24 months after the event, including an evaluation of depressive symptoms using the Geriatric Depression Scale. CCR5-Δ32 status and a baseline depression evaluation were available for 435 patients. Compared with noncarriers, CCR5-Δ32 carriers (16.1%) had fewer depressive symptoms at admission (p = 0.035) and at 6 months (p < 0.001), 12 months (p < 0.001) and 24 months (p = 0.006) after the index event. This association remained significant at 6 and 12 months after adjustment for age, sex, education, antidepressant use, ethnicity and the presence of cortical infarcts. These findings were more robust in women. Compared to baseline, depressive symptoms in CCR5-Δ32 noncarriers tended to remain stable or grow worse over time, but in CCR5-Δ32 carriers, symptoms tended to improve. A limitation of this study was the exclusion of patients who had a severe stroke or who had pre-stroke depression. Carriers of the CCR5-Δ32 allele had a lower tendency to develop depressive symptoms post-stroke, and this phenomenon was more prominent in women. These findings could have clinical implications; they suggest a mechanism-based treatment target for post-stroke depression. Drugs mimicking this loss-of-function mutation exist and could serve as a novel antidepressant therapy.
Sections du résumé
Background
A naturally occurring loss-of-function mutation in the gene for C-C chemokine receptor type 5 (CCR5-Δ32) has recently been reported as a protective factor in post-stroke motor and cognitive recovery. We sought to examine whether this mutation also prevented the development of depressive symptoms up to 2 years after a stroke.
Methods
Participants were survivors of a first-ever mild to moderate ischemic stroke or transient ischemic attack from the TABASCO prospective study who underwent a 3 T MRI at baseline and were examined by a multiprofessional team 6, 12 and 24 months after the event, including an evaluation of depressive symptoms using the Geriatric Depression Scale.
Results
CCR5-Δ32 status and a baseline depression evaluation were available for 435 patients. Compared with noncarriers, CCR5-Δ32 carriers (16.1%) had fewer depressive symptoms at admission (p = 0.035) and at 6 months (p < 0.001), 12 months (p < 0.001) and 24 months (p = 0.006) after the index event. This association remained significant at 6 and 12 months after adjustment for age, sex, education, antidepressant use, ethnicity and the presence of cortical infarcts. These findings were more robust in women. Compared to baseline, depressive symptoms in CCR5-Δ32 noncarriers tended to remain stable or grow worse over time, but in CCR5-Δ32 carriers, symptoms tended to improve.
Limitations
A limitation of this study was the exclusion of patients who had a severe stroke or who had pre-stroke depression.
Conclusion
Carriers of the CCR5-Δ32 allele had a lower tendency to develop depressive symptoms post-stroke, and this phenomenon was more prominent in women. These findings could have clinical implications; they suggest a mechanism-based treatment target for post-stroke depression. Drugs mimicking this loss-of-function mutation exist and could serve as a novel antidepressant therapy.
Identifiants
pubmed: 34291627
doi: 10.1503/jpn.200197
pmc: PMC8519488
doi:
Substances chimiques
CCR5 protein, human
0
Receptors, CCR5
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E431-E440Informations de copyright
© 2021 CMA Joule Inc. or its licensors.
Déclaration de conflit d'intérêts
None declared.
Références
Pharmacol Rep. 2014 Oct;66(5):920-6
pubmed: 25150002
N Engl J Med. 2008 Oct 2;359(14):1442-55
pubmed: 18832245
BMC Neurol. 2014 Oct 01;14:198
pubmed: 25269762
J Infect Dis. 2008 Jan 15;197(2):266-9
pubmed: 18179389
Int Psychogeriatr. 1991 Spring;3(1):23-8
pubmed: 1863703
Diabetes. 2005 Nov;54(11):3331-5
pubmed: 16249462
PLoS One. 2017 Jun 8;12(6):e0175790
pubmed: 28594820
J Infect Dis. 2014 Mar;209(6):922-30
pubmed: 24179109
Inflammation. 2015 Apr;38(2):902-10
pubmed: 25380845
J Am Geriatr Soc. 2005 Sep;53(9):1570-6
pubmed: 16137289
Clin Chem. 1991 Feb;37(2):241-4
pubmed: 1993332
Br J Psychiatry. 2013 Jan;202(1):14-21
pubmed: 23284148
J Alzheimers Dis. 2018;65(4):1365-1375
pubmed: 30149451
J Immunol. 2005 May 15;174(10):6023-9
pubmed: 15879095
J Exp Med. 2005 Oct 17;202(8):1087-98
pubmed: 16230476
Biol Psychiatry. 2016 Dec 1;80(11):812-814
pubmed: 27968725
Int J Stroke. 2014 Dec;9(8):1017-25
pubmed: 25117911
Cell. 2019 Feb 21;176(5):1143-1157.e13
pubmed: 30794775
Am J Psychiatry. 1993 Jan;150(1):124-9
pubmed: 8417554
Genet Med. 2004 May-Jun;6(3):126-31
pubmed: 15354329
Nature. 2016 Apr 28;532(7600):459-64
pubmed: 27074502
N Engl J Med. 2008 Jan 3;358(1):55-68
pubmed: 18172175
Biol Psychiatry. 2015 Nov 15;78(10):730-6
pubmed: 25708227
J Neurol Neurosurg Psychiatry. 2013 Mar;84(3):322-8
pubmed: 23236014
Psychol Med. 1994 Feb;24(1):145-53
pubmed: 8208879
Int J Stroke. 2012 Jun;7(4):341-7
pubmed: 22044517
Arch Intern Med. 1998 May 25;158(10):1133-8
pubmed: 9605786
Nat Med. 2016 Mar;22(3):238-49
pubmed: 26937618
Biomed Pharmacother. 1997;51(10):469-73
pubmed: 9863508
Mol Psychiatry. 2008 Dec;13(12):1093-101
pubmed: 19008895
Elife. 2016 Dec 20;5:
pubmed: 27996938
Curr Opin Psychiatry. 2011 Nov;24(6):519-25
pubmed: 21897249
J Neurosci. 2010 Oct 20;30(42):14116-26
pubmed: 20962232
Br J Pharmacol. 2010 May;160(2):311-21
pubmed: 20423342
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846
Neuro Endocrinol Lett. 2014;35(2):104-9
pubmed: 24878979
Genes Immun. 2000 Aug;1(6):358-61
pubmed: 11196681
Clin Exp Rheumatol. 2006 Sep-Oct;24(5 Suppl 42):S91-4
pubmed: 17067435
J Immunol. 2019 May 1;:
pubmed: 31043478
Appl Transl Genom. 2013 May 26;2:3-16
pubmed: 27942440
J Clin Psychiatry. 2016 May;77(5):673-80
pubmed: 27035632
Am J Psychiatry. 2016 Mar 1;173(3):221-31
pubmed: 26684921
Front Psychiatry. 2018 Dec 17;9:682
pubmed: 30618863
Pharmacol Res. 2019 May;143:106-112
pubmed: 30904753